Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

Visit https://www.peervoice.com/TUH860 to view the entire programme with slides. After completing “Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML”, participants will be able to: Recall clinical trial data evaluating first- and second-generation FLT3 inhibitors in the management of newly diagnosed FLT3-mutant acute myeloid leukemia (AML); Implement best practice approaches to using FLT3 inhibitors in practice, including selecting between therapeutics and utilizing recommended dose schedules; and Formulate adverse event management strategies for patients receiving treatment with a FLT3 inhibitor, including monitoring and supportive treatment.